Deep Longevity Launches The First Longevity Medicine Course For Physicians

HONG KONG, Nov. 18, 2020 /PRNewswire/ — Regent Pacific Group Limited (“Regent Pacific” or the “Company” and together with its subsidiaries, the “Group”; SEHK:0575.HK)’s Deep Longevity, Inc, a company subject to a conditional acquisition by the Group which is a pioneer in deep biomarkers of aging and longevity today announced the launch of the first Longevity Medicine course for Physicians on LabXchange Platform. It is the first of several Longevity Medicine chapters, with upcoming courses scaled for scientists and patients.

This course is aimed to fill the educational gap in translation longevity medicine. Deep Longevity, a leader in artificial intelligence for the development of biomarkers of aging and longevity, brought together scientists and physicians engaged in basic and translational research to develop the course: “Longevity Medicine for Physicians”. The course covers basics in translational aging research from terminology and demographic aspects, theories and hallmarks of aging, basic aging pathways and mechanisms behind the possibly geroprotective interventions and covers the various types of aging clocks.

The course is intended for medical professionals and students, who have limited time and seek a comprehensive, well-structured, reliable course. It contains three hours of core lectures providing an introduction to the field, lecture slides, lecture notes, quizzes, guest lectures, as well as references to additional reading materials and online resources. Introduction to Longevity Medicine is the first course in a series intended to provide advanced physicians with the latest approaches in longevity technology.

“As we are partnering with the advanced clinical institutions we see the gap between translational research and clinical practice and would like to provide the MDs with the resources they need to get into the rapidly growing field of longevity medicine, learn about the latest advances in artificial intelligence and in the pharmaceutical industry”, said Alex Zhavoronkov, PhD, the founder of the Longevity Medicine course and Chief Longevity Officer at Deep Longevity.

“While much-scattered information is available from more or less evidence-based sources, there was a lack of a structured, guided and well organized course that provides physicians with the necessary background information on this rapidly evolving discipline of healthy longevity. This is why we developed this very first course in Longevity Medicine – to close this gap and provide understandable and practicable, credible resources for clinicians”, said Evelyne Bischof, MD, co-founder of the course.

Earlier this year, Deep Longevity received investments from expert longevity investment funds related to clinical organizations and is currently subject to a conditional acquisition by Regent Pacific Group Limited (SEHK:0575.HK), a public company whose securities are listed on The Stock Exchange of Hong Kong Limited. It also announced a partnership with Human Longevity Inc, one of the world’s most advanced centers for preventative diagnostic medicine. Since then, it has partnered with several other advanced clinics and hospitals.

For details of the course, please visit: longevity-medicine.org  

This press release is distributed by LBS Communications Consulting Limited.

About Deep Longevity

Deep Longevity is subject to a conditional acquisition by Regent Pacific Group Limited (SEHK:0575.HK), a public

Read More

Women In Longevity Medicine And The Rise Of The Longevity Physician

Over the past decade, we witnessed unprecedented advances in the field of biogerontology, and the massive convergence of biotechnology, information technology, AI, and medicine. And now we are witnessing the birth of a new field of longevity medicine, which integrates the latest advances in many of these fields of science and technology. My definition longevity medicine is advanced personalized preventative medicine powered by deep biomarkers of aging and longevity.

And, like in the field of AI for drug discovery, women are at the forefront of this revolution and there were precedents when we had to look for a male physician to make a conference panel more diverse. 

One of the physician-scientists who stands out in this area is Dr. Evelyne Yehudit Bischof. I first got a note with a request for more information on one of our research papers from Dr. Bischof on December 30th, 2019 while in Shanghai. A request I almost ignored due to the heavy workload but accidentally I looked at her profile which was highly unusual. In brief, Evelyne is a German medical doctor with an MD from Max Planck Institute for Molecular Biology and Genetics, who interned at Columbia University, and Harvard MGH and Beth Israel Medical Deaconess, attending physician at University Hospital Basel in Switzerland, and associate professor at Shanghai University of Medicine and Health Sciences.  She fluently spoke six languages including German, Russian, and Mandarin Chinese, which was quite impressive. The second time we met was at Human Longevity Inc, in San Diego when she was interviewing with one of the most influential entrepreneurs and investors in longevity biotechnology, Dr. Wei-Wu He to join HLI as a longevity physician.

The longevity industry is rapidly emerging and longevity clinics are being set up in various parts of the world. So I decided to ask Eva a few questions to elucidate this new and emerging industry. 

Alex: Eva, we know each other for almost a year and you do not fail to impress with your academic publications, public lectures, and clinical work. You are as close to the “longevity physician” as it can possibly get. Can you tell us a bit more about yourself and about the work that you are doing on the clinical side and on the research side? 

Dr. Evelyne Bischof: Thank you, Alex – it is an honor to be so generously introduced by a true innovator, scientist and entrepreneur, as well as a longevity KOL and allow me to revert the compliment. I am a rather globally oriented internal medicine specialist, with training and work experience in Germany, USA, Switzerland and China. For almost a decade now, I have been splitting my time between Shanghai and Basel, creating a path that allowed me to conclude my residency and fellowship, develop translational and clinical research niches and collaborators, as well as to engage actively in academic medical education. While

Read More